Among the most commonly mutated genes, several involve the Jak-STAT, MAPK, and ROCK signaling pathways, which could be actionable with targeted therapies that are already used in clinical practice, opening the way to tailored treatment in aCML. This evidence concerns the gene SOAT1 and atypical chronic myeloid leukemia, BCR-ABL1 negative.